Evaluation of somatostatin receptors in large cell pulmonary neuroendocrine carcinoma with 99mTc-EDDA/HYNIC-TOC scintigraphy

Nocuń, Anna; Chrapko, Beata; Golebiewska, R.; Stefaniak, Bogusław; Czekajska−Chehab, Elżbieta

doi:10.1097/mnm.0b013e32834508b3

Cited by 8 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An analysis of somatostatin receptor scintigraphy in pulmonary LCNEC was done in 26 patients with technetium-99m ethylene diamine-diacetic acid/hydrazinonicotinyl-Tyr3octreotide (Tc-TOC). This study found that 100% of primary lesions showed uptake of Tc-TOC while 84% of metastases were visualized (as compared to conventional imaging) (149). Another study retrospectively examined 26 patients with primary pulmonary LCNEC and compared them to 40 patients with adenocarcinoma.…”

Section: Future Directionsmentioning

confidence: 95%

Management of Large Cell Neuroendocrine Carcinoma

et al. 2021

View full text Add to dashboard Cite

BackgroundLarge cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive cancer with a dismal prognosis. The majority of cases occur in the lung and the gastrointestinal tract; however, it can occur throughout the body. Recently advances in the understanding of the molecular underpinnings of this disease have paved the way for additional novel promising therapies. This review will discuss the current best evidence for management of LCNEC and new directions in the classification and treatment of this rare disease.MethodsWe performed a PubMed search for “Large cell neuroendocrine carcinoma” and “High grade neuroendocrine carcinoma.” All titles were screened for relevance to the management of LCNEC. Papers were included based on relevance to the management of LCNEC.ResultsPapers were included reviewing both pulmonary and extra pulmonary LCNEC. We summarized the data driven best practices for the management of both early and advanced stage LCNEC. We describe emerging therapies with promising potential.DiscussionLCNEC are rare and aggressive neoplasms. In advanced disease, the historical regimen of platinum based therapy in combination with etoposide or irinotecan remains among the commonly used first line therapies, however for extra thoracic LCNEC regimens like FOLFOX, FOLFOIRI and CAPTEM can also be used. Further effective and safe treatment options are desperately needed. Recently, new advances including a new understanding of the genetic subcategories of LCNEC and immunotherapy agents may guide further treatments.

show abstract

Section: Future Directionsmentioning

confidence: 95%

Management of Large Cell Neuroendocrine Carcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…And optimized as follows: in a rubber-sealed vial, 10 μg of peptide was incubated with 1 mL of EDDA/tricine solution (20 mg tricine, 10 mg EDDA in PBS buffer, pH 6-7), 1 mL of 99mTcO 4 solution (450 MBq) and 20 µL of tin(II) solution (10 mg of SnCl 2 in 10 mL of 0.1 N HCl) for 15 min at 100 °C. Reactions were then cooled down at room temperature (Decristoforo et al 2006;Nocun et al 2011). After that, the mixture was purified by Sep-Pak C-18 cartridges (Waters Company, America) following the protocol of previous descriptions.…”

Section: Peptide Synthesis and Radioactive Labelingmentioning

confidence: 99%

SPECT imaging of interleukin-6 receptor in ovarian tumor xenografts with a novel radiotracer of 99mTc-HYNIC-Aca-LSLITRL

Zhang

Cheng

et al. 2015

Amino Acids

View full text Add to dashboard Cite

Growing evidences have shown that the IL-6/IL-6R signal pathway promotes the tumor growth, angiogenesis, invasion and migration in various cancers, especially for epithelial ovarian cancer. Hence, including anti-IL-6 antibody (Siltuximab) and anti-IL-6R antibody (Tocilizumab), more and more therapeutic drugs targeting IL-6/IL-6R pathway were developed to block their activity. The molecular imaging of IL-6R is a significant factor for predicting tumor response to IL-6/IL-6R targeted drugs. However, few probes targeting IL-6R were designed and used for the specific detection. The purpose of this study was to develop and evaluate a novel radiotracer, (99m)Tc-HYNIC-Aca-LSLITRL, for SPECT imaging of interleukin-6 receptor. The expression of IL-6R was determined by western blot, immunofluorescence and immunohistochemistry. HYNIC-Aca-LSLITRL and HYNIC-Aca-TLQASIL were synthesized, and then were labeled with 99mTc. The stability and the cell-binding assay were performed. Ovarian tumor xenografts were established and subjected to SPECT imaging after injection of these two radiopharmaceuticals with or without excess primary peptides. The biodistribution of these two radiotracers was performed in nude mice bearing C13K tumors. (99m)Tc-HYNIC-Aca-LSLITRL and (99m)Tc-HYNIC-Aca-TLQASIL were obtained in >95 % labeling yield with favorably stability. In vitro studies demonstrated that the interleukin-6 receptor was overexpressed in ovarian cancer C13K cells. The SPECT imaging of interleukin-6 receptor and biodistribution studies showed that (99m)Tc-HYNIC-Aca-LSLITRL had higher tumor uptake and significantly lower kidney accumulation compared to (99m)Tc-HYNIC-Aca-TLQASIL. (99m)Tc-HYNIC-Aca-LSLITRL could be a promising agent for SPECT imaging of interleukin-6 receptor of ovarian cancer especially for those anti-IL-6R drugs under clinical trials, such as tocilizumab.

show abstract

“…At the beginning of this century, two new 99m Tc-labelled SST analogues were introduced: [ 99m Tc]Tc-N4-[Tyr3] Octreotate (Demotate ® , POLATOM, Otwock, Poland) and [ 99m Tc]Tc-EDDA/HYNIC-[Tyr3] Octreotide (Tektrotyd ® , POLATOM, Otwock, Poland) [11], both of which are widely used in clinical practice with major advantages over [ 111 In]In-Octreotide [12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27].…”

Section: Introductionmentioning

confidence: 99%

Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review

Carideo

Prosperi

Panzuto

et al. 2019

JCM

View full text Add to dashboard Cite

Gastro-entero-pancreatic neuroendocrine neoplasia (GEP-NENs) are rare tumors, but their frequency is increasing. Neuroendocrine tumors normally express somatostatin (SST) receptors (SSTR) on cell surface, especially G1 and G2 stage tumors, but they can show a dedifferentiation in their clinical history as they become more aggressive. Somatostatin receptor imaging has previously been performed with a gamma camera using [111In]In or [99mTc]Tc-labelled compounds, while [68Ga]Ga-labelled compounds and PET/CT imaging has recently become the gold standard for the diagnosis and management of these tumors. Moreover, in the last few years 18F-fluorodeoxyglucose ([18F]FDG) PET/CT has emerged as an important tool to define tumor aggressiveness and give relevant prognostic information, particularly when coupled with [68Ga]Ga-labelled SST analogues PET/CT. This review focuses on the importance of combined imaging with [68Ga]Ga-labelled SST analogues and [18F]FDG for the management of GEP-NENs.

show abstract

Evaluation of somatostatin receptors in large cell pulmonary neuroendocrine carcinoma with 99mTc-EDDA/HYNIC-TOC scintigraphy

Abstract: Within a rather large series of LCNEC, the primary tumor showed an uptake of Tc-TOC in all cases, whereas some metastases did show Tc-TOC uptake and some others did not.

Cited by 8 publications

References 1 publication

Management of Large Cell Neuroendocrine Carcinoma

Management of Large Cell Neuroendocrine Carcinoma

SPECT imaging of interleukin-6 receptor in ovarian tumor xenografts with a novel radiotracer of 99mTc-HYNIC-Aca-LSLITRL

Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review

Contact Info

Product

Resources

About